Background And Purpose: Breast cancer is one of the most widely recognized tumors. .Diagnosis made in the early stage of disease may imporve outcomes. The discovery of malignant growth utilizing noninvasive light intrusive methods in lieu of conventional excisional biopsy may assist in achieving this goal.
Materials And Methods: The change of the optical properties of ex-vivo breast tissues provides different responses to light transmission, absorption, and particularly the reflection over the spectrum range. We offer the use of Hyperspectral imaging (HSI) with advanced image processing and pattern recognition in order to analyze HSI data for breast cancer detection. The spectral signatures were mined and evaluated in both malignant and normal tissue. K-mean clustering was designed for classifying hyperspectral data in order to evaluate and detection of cancer tissue. This method was used to detect ex-vivo breast cancer. Spatial spectral images were created to high spot the differences in the reflectance properties of malignant versus normal tissue.
Results: Trials showed that the superficial spectral reflection images within 500 nm wavelength showed high variance (214.65) between cancerous and normal breast tissues. On the other hand, image within 620 nm wavelength showed low variance (0.0020).However, the superimposed of spectral region 420-620 nm was proposed as the optimum bandwidth. Finally, the proposed HS imaging system was capable to discriminate the tumor region from normal tissue of the ex-vivo breast sample with sensitivity and a specificity of 95 % and 96 %.
Conclusions: High sensitivity and specificity were achieved, which proposes potential for HSI as an edge evaluation method to enhance the surgical outcome compared to the presently available techniques in the clinics.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.pdpdt.2020.101922 | DOI Listing |
Heliyon
January 2025
BRITElab, Harry Perkins Institute of Medical Research, QEII Medical Centre Nedlands and Centre for Medical Research, The University of Western Australia, Perth, Australia.
Breast-conserving surgery accompanied by adjuvant radiotherapy is the standard of care for patients with early-stage breast cancer. However, re-excision is reported in 20-30 % of cases, largely because of close or involved tumor margins in the specimen. Several intraoperative tumor margin assessment techniques have been proposed to overcome this issue, however, none have been widely adopted.
View Article and Find Full Text PDFTechnol Cancer Res Treat
January 2025
Breast surgery, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
We conducted a systematic review to compile the findings of all published studies on the use of percutaneous laser ablation (PLA) in the treatment of early-stage breast cancer. We aimed to identify appropriate methodology as well as parameters for the selection of suitable patients to optimize outcomes with the use of PLA. Additionally, we aimed to analyze whether this method is a viable alternative to current surgical treatments employed.
View Article and Find Full Text PDFJ Immunother Cancer
December 2024
Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California, USA
Background: Granzyme B (GrB) is a key effector molecule, delivered by cytotoxic T lymphocytes and natural killer cells during immune surveillance to induce cell death. Fusion proteins and immunoconjugates represent an innovative therapeutic approach to specifically deliver a deadly payload to target cells. Epithelial membrane protein-2 (EMP2) is highly expressed in invasive breast cancer (BC), including triple-negative BC (TNBC), and represents an attractive therapeutic target.
View Article and Find Full Text PDFBiomark Res
January 2025
Institute of Biochemistry and Molecular Biology, College of Life Sciences, China Medical University, Taichung, Taiwan.
Background: Up to 23% of breast cancer patients recurred within a decade after trastuzumab treatment. Conversely, one trial found that patients with low HER2 expression and metastatic breast cancer had a positive response to trastuzumab-deruxtecan (T-Dxd). This indicates that relying solely on HER2 as a single diagnostic marker to predict the efficacy of anti-HER2 drugs is insufficient.
View Article and Find Full Text PDFCancers (Basel)
December 2024
Department of Obstetrics and Gynecology, Heidelberg University Hospital, Im Neuenheimer Feld 440, 69120 Heidelberg, Germany.
The pretherapeutic assessment of axillary lymph node status is crucial in staging early breast cancer patients, significantly influencing their further treatment and prognosis. According to current guidelines, patients with clinically unsuspicious axillary status regularly undergo a biopsy of sentinel lymph nodes (SLNs), whereby metastasis is detected in up to 20% of cases. In recent years, the use of shear wave elastography (SWE) has been studied as an additional ultrasound tool for the non-invasive assessment of tumors in the breast parenchyma and axillary lymph nodes.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!